Translational Considerations in the Development of Intranasal Treatments for Epilepsy

被引:3
|
作者
Prentice, Richard N. [1 ]
Rizwan, Shakila B. [1 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin 9016, New Zealand
关键词
epilepsy; seizure; intranasal; anti-seizure medication; nose-to-brain; olfactory; drug delivery; TO-BRAIN DELIVERY; NANOSTRUCTURED LIPID CARRIERS; DRUG-DELIVERY; PIRIFORM CORTEX; ANTIEPILEPTIC DRUGS; ANIMAL-MODELS; PHARMACOLOGICAL FACTORS; LABORATORY EVALUATION; ANTICONVULSANT DRUGS; HZ;
D O I
10.3390/pharmaceutics15010233
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Epilepsy is a common and serious neurological disorder, to which a high proportion of patients continue to be considered "drug-resistant", despite the availability of a host of anti-seizure drugs. Investigation into new treatment strategies is therefore of great importance. One such strategy is the use of the nose to deliver drugs directly to the brain with the help of pharmaceutical formulation to overcome the physical challenges presented by this route. The following review explores intranasal delivery of anti-seizure drugs, covering the link between the nose and seizures, pathways from the nose to the brain, current formulations in clinical use, animal seizure models and their proposed application in studying intranasal treatments, and a critical discussion of relevant pre-clinical studies in the literature.
引用
收藏
页数:35
相关论文
共 50 条
  • [1] Development of phenytoin intranasal microemulsion for treatment of epilepsy
    Acharya S.P.
    Pundarikakshudu K.
    Upadhyay P.
    Shelat P.
    Lalwani A.
    Journal of Pharmaceutical Investigation, 2015, 45 (4) : 375 - 384
  • [2] Regulatory, Translational, and Operational Considerations for the Incorporation of Biomarkers in Drug Development
    Hatcher, Heather
    Stankeviciute, Simona
    Learn, Chris
    Qu, Angela X.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2025, : 519 - 526
  • [3] Methodological considerations for the development of new treatments for bipolar disorder
    Potter, WZ
    Ozcan, ME
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1999, 33 : S84 - S98
  • [4] Translational epilepsy research
    Cavalheiro, E. A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S31 - S31
  • [5] Barriers to the use of genetic information for the development of new epilepsy treatments
    Ferraro, Thomas N.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (01) : 5 - 8
  • [6] Biomarker development for translational geroscience: Considerations for a strategic framework focusing on early clinical development
    Sanders, Jason L.
    AGING CELL, 2023, 22 (05)
  • [7] Clinical Pharmacology and Translational Considerations in the Development of CRISPR-Based Therapies
    Abdelhady, Ahmed M.
    Phillips, Jonathan A.
    Xu, Yuanxin
    Stroh, Mark
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (03) : 591 - 603
  • [8] The safety and tolerability of intranasal midazolam in epilepsy
    Mula, Marco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (07) : 735 - 740
  • [9] Low-dose intranasal insulin improves cognitive function and suppresses the development of epilepsy
    Peng, Shu
    Yang, Jin
    Wang, Yufeng
    Fan, Yang
    Tang, Feng
    Hou, Changyue
    Yu, Juming
    Wang, Xiaoming
    Jiang, Guohui
    BRAIN RESEARCH, 2020, 1726
  • [10] A strategy for translational epilepsy research
    Treiman, David M.
    EPILEPSY RESEARCH, 2017, 129 : 86 - 86